Background The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …

The recognition that hepatocellular carcinoma (HCC) is a rising problem globally dates back
decades; however, the development of effective medical treatment for the disease has only …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, with
up to 90% of HCC cases occurring in the setting of underlying cirrhosis. Therapeutic …

Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy
has been explored in this disease in order to improve survival outcomes. Nowadays …

Introduction: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and
the third cancer-related cause of death worldwide. In recent years, several systemic therapy …

Background This study aimed to evaluate safety and efficacy of programmed death-1 (PD-1)
inhibitor sintilimab plus tyrosine kinase inhibitors (TKI) in a real-word cohort of patients with …

Background and Aims Recent development of multiple treatments for human hepatocellular
carcinoma (HCC) has allowed for the selection of combination therapy to enhance the …

Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally and is rising in
incidence. Until recently, treatment options for patients with advanced stages of HCC have …

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with
hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of …

Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of
sorafenib treatment were included. Primary endpoint was overall survival (OS) and …